Drug Database
CE

cefaclor (Raniclor / Raniclor)

✓ Approved

Ranbaxy Laboratories Limited · Small Molecule · Small Molecule

What is cefaclor?

cefaclor is a small molecule developed by Ranbaxy Laboratories Limited. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesRaniclor, Raniclor
CompanyRanbaxy Laboratories Limited
Drug ClassSmall Molecule
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Ranbaxy Laboratories Limited

Therapeutic Indications

cefaclor is developed for 6 unique indications across 3 therapeutic areas.

Therapeutic AreaConditionPhase
Infections and infestationsLower respiratory tract infection✓ Approved
Infections and infestationsOtitis media✓ Approved
Infections and infestationsTonsillitis✓ Approved
Infections and infestationsUrinary tract infection✓ Approved
Respiratory, thoracic and mediastinal disordersTonsillar inflammation✓ Approved

+1 more indication available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedInternational journal of pharmaceutical compounding2026-09-17

Formulation and E-Tongue Evaluation of Taste-Masked Chewable Ferrous Ascorbate Tablets Using Design of Experiment.

Rajagopal Kumaravelrajan K, Sekar Satyanarayanan S, Muthusamy Kannan K, William Clement Atlee CA et al.

This study aims to develop and optimize taste-masked chewable iron tablets using Hydroxypropyl beta-cyclodextrin (HPßCD) and E-Tongue technology to improve patient compliance. A 2-level factorial design was employed to evaluate the effects of HPßCD, isomaltose, and Pearlitol® on the formulation. By using design of experiment the effect of each factor individually on the response can be predicted. There are 8 runs in this design the response for each 8 formulations is predicted individually by using design expert software. The composition of the tablet formulation was optimized using full factorial 23design, which is desirable for response surface methodology to optimize complex formulations. The results demonstrated favorable flow properties, with consistent bulk and tapped densities, and excellent mechanical strength, particularly for F8. In-vitro dissolution studies revealed a high cumulative drug release (93.75%) for F8. E-Tongue analysis indicated that F8 exhibited superior taste-masking efficiency, with the lowest bitterness score. The optimised chewable tablet evaluated for bitter score and hardness. According to point prediction mean predicted was found to be 4.1 for bitter score and observed mean was 4 and for hardness the predicted mean was 13kg/density and observed mean was 14 kg/density. Therefore, the optimised formulation F9 was Drug:CD (1:5), Sweetening agent (11.25mg) and Pearlitol (90 mg) Additionally, chewability was influenced by tablet hardness, with F8 showing the highest chewability difficulty index. The optimized formulation (F8) provides a balanced combination of taste masking, drug release, and mechanical strength, enhancing patient adherence.

PMID 42752429
Read full article →
PubMedFrontiers in pediatrics2026-09-08

Association between the timing of chewable complementary food introduction and functional speech disorders in children: a case-control study.

Li Houbin H, Huang Guilian G, Qi Qiang Q

To investigate the association between the timing of chewable complementary food introduction and functional speech disorders (FSD) in children, and to identify independent risk and protective factors with a primary focus on quantifying the effect of delayed chewable food introduction. A case-control study was conducted including 90 children diagnosed with FSD and 90 healthy controls aged 2-8 years. Data were collected on demographic characteristics, electronic screen exposure, parent-child interaction, perinatal risk factors, and complementary feeding practices. Univariate and multivariate logistic regression analyses were performed to assess independent associations. Delayed introduction of chewable complementary foods (≥12 months) was the strongest independent risk factor for FSD (fully adjusted OR = 35.20, 95% CI: 10.15-122.04, P < 0.001). Prolonged screen exposure (>2 h/day) and perinatal high-risk factors were additional risk factors. Female gender and increased parent-child interaction (>2 h/day) were protective factors. Subgroup analyses confirmed the stability of the main association across gender, age, and screen exposure subgroups. Delayed introduction of chewable complementary foods beyond 12 months is a critical, independent, and modifiable risk factor for childhood FSD. Timely introduction of chewable foods before age 1 year, combined with limited screen time and enhanced parent-child interaction, may serve as a reference to lower FSD risk in early childhood.

PMID 42707382
Read full article →
PubMedFrontiers in oral health2026-09-06

Evaluation of the plaque removal efficacy of chewable toothpaste tablets - a randomized controlled crossover trial.

Srivastava Harshit H, Chhabra Kumar Gaurav KG, S Naganandini N, Chaudhary Pankaj P et al.

Chewable toothpaste tablets (CTTs) have recently emerged as environmentally sustainable alternatives to conventional toothpaste formulations. However, limited scientific evidence is available regarding their clinical efficacy in plaque control. The present study aimed to compare the antiplaque efficacy and user acceptability of two commercially available chewable toothpaste tablets among young adults. A randomized double-blind crossover clinical trial was conducted among 196 adults aged 18-35 years. Participants were randomly allocated into two intervention sequence groups (AB and BA). Sequence AB used Apollo Noni CTT for 7 days followed by Teeth-A-Bit after a 7-day washout period, whereas Sequence BA followed the reverse sequence. Plaque scores were recorded using the Modified Turesky-Gilmore-Glickman Plaque Index following 24-h abstinence from oral hygiene procedures at baseline and after each intervention phase. Participant feedback was assessed using a structured questionnaire. Data were analyzed using descriptive statistics, chi-square tests, and linear mixed-effects modeling with restricted maximum likelihood estimation. A total of 196 participants (95 men, 101 women; mean age 23.42 ± 2.65 years) completed the study. Baseline plaque scores were comparable between the AB and BA treatment sequences (Period 1: 1.82 ± 0.24 vs. 1.77 ± 0.25; Period 2: 1.77 ± 0.26 vs. 1.80 ± 0.19). Following the 7-day intervention, plaque scores decreased in both sequences, with lower post-intervention scores observed for Apollo Noni (1.34 ± 0.27 and 1.32 ± 0.21) than for Teeth-A-Bit (1.54 ± 0.24 and 1.52 ± 0.27). Linear mixed-effects analysis showed baseline plaque score significantly predicted post-treatment score (p < 0.001). After adjustment, Apollo Noni achieved significantly lower plaque scores than Teeth-A-Bit (1.322 ± 0.010 vs. 1.548 ± 0.010; mean difference -0.226, 95% CI: -0.245 to -0.206; p < 0.001). No significant period or sequence effects were found, indicating no carryover bias. Both products were well-accepted, with no adverse effects or significant gender-based differences in user experience or satisfaction (p > 0.05). Both CTTs reduced dental plaque, but Apollo Noni demonstrated noticeably greater antiplaque efficacy. The results indicate that CTTs may offer viable, eco-friendly substitutes for traditional dentifrices. https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=MTEwNTg2&Enc=&userName=, Clinical Trials Registry-India (CTRI/2024/07/070865).

PMID 42698468
Read full article →
PubMedJournal of chromatographic science2026-09-04

QbD consideration for developing and validating the dissolution test method for quantitative analysis of tadalafil chewable tablets.

Park Seung-Hyun SH, Kim Joo-Eun JE

Erectile dysfunction (ED) is defined as the persistent inability to achieve or maintain an erection sufficient for satisfactory performance for a duration of >3 months. However, chewable tadalafil formulations for treating ED and corresponding dissolution analysis methods for their quantification are lacking. Therefore, this study aims to investigate Quality by Design considerations for developing a reversed-phase high-performance liquid chromatography method. The test method was designed to perform a quantitative dissolution analysis of tadalafil chewable tablets to enhance medication compliance. This method required an Agilent C8 column (4.6 × 5.0 cm, 5 μm) as the stationary phase and a mobile phase comprising a 1:1 methanol-water mixture. The column temperature and detection wavelength were maintained at 40°C and 225 nm, respectively. The development and validation of the dissolution method resulted in a relative standard deviation of 0.03% for system suitability, assessed in a test solution containing a solubilizer. The test method demonstrated specificity by clearly distinguishing the active pharmaceutical ingredient from excipients. Tadalafil accuracy was confirmed with an average recovery rate of 100.22%, and the precision showed a relative standard deviation of 0.35%. Excellent linearity (R2 = 1.000) was observed over the concentration range of 1.5 μg/mL to 9.0 μg/mL. Additionally, the detection and quantification limits for tadalafil were 0.003 μg/mL and 0.008 μg/mL, respectively. The developed method facilitated rapid quantification of tadalafil in chewable tablets, completing each run within 5 min and reducing analysis time by ~60% compared to conventional methods. Additionally, reagent consumption and operational costs were reduced by ~45%, improving overall efficiency. These findings validate the suitability of the method for reliable industrial quality control of tadalafil chewable tablets and new formulations.

PMID 42696759
Read full article →
PubMedParasites & vectors2026-09-04

Efficacy of lotilaner (Credelio™ chewable tablets) for preventing Babesia canis transmission to dogs by infected Dermacentor reticulatus ticks.

Deuster Katrin K, Webb Laura A LA, Rautenbach Carin C, Anderson William E WE et al.

Canine babesiosis is a clinically significant tick-borne disease, caused by different Babesia species. Babesia canis, one of the most important and widespread species in Europe, is transmitted by Dermacentor reticulatus ticks and can cause potentially fatal canine disease. Prevention of pathogen transmission can be achieved by regular tick control and prophylaxis. The present study evaluated the efficacy of a single oral application of lotilaner (Credelio™, Elanco) in dogs for blocking pathogen transmission compared to a negative control group. Twenty-four B. canis-negative dogs were allocated to three groups (n = 8 each). The two treatment groups were treated once orally with Credelio either on Day 0 or 23, while the negative control was sham-dosed accordingly. All dogs were challenged with B. canis-infected D. reticulatus on Day 28, i.e., 28- or 5-days post-treatment (p.t.), for the lotilaner-treated groups. Tick efficacy was assessed by in situ tick counts 24 and 48 h after infestation (Days 29 and 30) and final tick counts and removals 120 h after infestation (Day 33). Clinical examinations, hematology (blood smear), serology (IFAT) and blood PCR were performed in all dogs systematically and in case of suspected clinical babesiosis. A single oral treatment with Credelio 28 or 5 days prior to infestation with B. canis-infected D. reticulatus resulted in 100% blocking efficacy against B. canis transmission, as compared to untreated dogs (p < 0.001). The lotilaner-treated dogs were healthy and did not show any clinical or hematological signs of B. canis infection. No treated dog seroconverted or showed a positive PCR. The untreated negative controls tested positive for B. canis from Day 35 onward. All negative controls developed B. canis infection by Day 36 (clinical signs, blood smear, PCR). From Day 43 onward, positive IFAT was also observed. Lotilaner administered on Day 0 or Day 23 demonstrated tick efficacy of 99.7 and 100%, respectively (Day 33). This study confirmed a single oral application of lotilaner chewable tablets was highly effective (100%) against D. reticulatus, blocking the transmission of B. canis to dogs at the beginning as well as at the end of the monthly treatment interval of Credelio.

PMID 42693474
Read full article →
PubMedJournal of biological engineering2026-08-26

Pharmaceutical polymer-based hydrogels for 3D bioprinted drug delivery and tissue engineering applications.

Bankhede Hemant Kumar HK, Sivaravi Maheswari M, Raiturker Antara Poi AP, Bhende Prajakta Praveen PP et al.

3D bioprinting enables the layer-by-layer fabrication of living tissue constructs and supports patient-specific customization. This technology holds strong promises for regenerative medicine and drug discovery. However, its broader translation remains limited by material variability, safety considerations, cost constraints and regulatory requirements. This study investigates the use of safe, affordable and regulatory-compliant pharmaceutical polymers as biomaterials for 3D bioprinting. It specifically focuses on hydrogels formulated from Starch 1500®, maltodextrin and sodium alginate. The objective is to assess their potential applications in skin tissue engineering and oral drug delivery through semisolid extrusion-based 3D bioprinting techniques. Ionic crosslinking of the hydrogel was confirmed by FTIR analysis. The hydrogel exhibited a viscosity of 1.56 × 106 mPa·s, supporting semisolid extrusion bioprinting and excellent printability under ambient conditions. It enabled the fabrication of multilayer scaffolds with uniform filaments, well-defined square pore geometry and good shape fidelity. Rheological analysis showed shear-thinning behavior under applied stress, 87% thixotropic recovery and predominantly solid-like behavior at rest. Cast films showed a tensile strength of 33.9 MPa with limited extensibility, whereas lyophilized scaffolds exhibited high porosity and an average pore size of 39.2 μm. The 3D-printed scaffolds swollen upto 72% within 24 h and showed the onset of degradation after 2 weeks. Biological evaluation confirmed non-cytotoxicity, with more than 70% cell viability in skin-relevant L929 and HaCaT cells and good hemocompatibility, indicated by 5.0% hemolysis. Confocal microscopy further showed cell growth on the crosslinked hydrogel, supporting their potential for skin tissue engineering. Glimepiride-loaded bioinks were successfully formulated into chewable tablets for drug delivery, which exhibited acceptable physical properties. The tablets demonstrated excellent content uniformity (100.4%), while dissolution results showed sustained-release profiles over a time period of four hours. Our research indicates that pharmaceutical-grade polymer-based hydrogels are promising candidates for skin tissue engineering and drug delivery through 3D bioprinting. The findings of this study underscore the potential of these formulations to advance bioprinting technologies and related applications.

PMID 42642767
Read full article →

+2769 more articles available with a free account

Sign up free to view all articles →

Ask about cefaclor